** Shares of medical device maker Inspire Medical Systems INSP.N rise 5.4% to $185.49
** BofA Global Research upgrades stock to "buy" from "neutral", citing co has "turned the corner on profitability" with two straight quarters of positive margins and durable cost control
** INSP makes of non-invasive devices for patients with a common sleeping disorder, which works by stimulating the nerve that controls tongue muscles
** Brokerage also raises price objective on INSP from $220 to $255, representing premium of 44.8% to stock's last close
** Doctors expect INSP devices will continue to hold 84% market share even if rival devices from LivaNova LIVN.O and Nyxoah NYXH.BR are approved, brokerage says
** BofA says INSP has "good visibility in 2025 growth" and can achieve estimates of $950 mln in 2025 revenue
** 14 of 19 brokerages rate stock "buy" or higher and 5 "hold"; their median PT is $251 - LSEG data
** As of last close, stock down 13.5% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.